

## Macro buffer utilization delivers stable Q1; hopes for a better H2

BFSI - NBFCs ▶ Result Update ▶ July 21, 2025

CMP (Rs): 203 | TP (Rs): 190

LTF reported a steady Q1FY26, with overall AUM crossing the Rs1trn mark and registering a 15% YoY (~13.8% excluding Gold Loans) growth, resulting from strong disbursements across the retail segment (including MFI and GL). Margins (NIM + fee) improved by ~7bps due to moderating CoFs. LTF has completed the integration of the acquired GL business and plans to expand branches to ~300 (from 135 now; including new geographies). Credit cost remained elevated in Q1 (Rs3bn of macro overly utilized in Q1) and the management expects MFI stress to peak in Q2FY26, with the growth momentum returning in H2. The focus on acquiring prime and near-prime customers, along with a broader rollout of Cyclops, is expected to help contain FY26 credit cost at 2.3–2.5%. Additionally, the mgmt plans to rebuild macro buffers using recoveries from the SR book, where several accounts are in advanced stages of resolution and proceeds are expected in FY27–28. Incorporating the Q1 performance and the outlook for H2, we tweak our estimates, resulting in 30-50bps change in FY26–28E RoE and 3-5% change in FY26–28E EPS; we retain REDUCE with a revised Jun-26E TP of Rs190 (up 6% from Rs180), implying FY27E P/B of 1.6x.

## RBI's rate cut and easing MFI stress drove growth and margin improvement

LTF reported PAT of Rs7.01bn, marginally higher than our estimated Rs7.8bn, primarily on account of improved margins led by the RBI's rate cut and easing stress in the MFI segment (utilized Rs3bn macro prudential buffer), resulting in improved income. Overall AUM registered 5%/15% QoQ/YoY growth, led by robust disbursements across products and integration of GL business. Credit cost remained elevated (calculated at 2.53%) in Q1FY26; the mgmt expects normalization in H2FY26 on Cyclops implementation and improving macros. Asset quality remained stable with GS3/NS3 at 3.31%/0.99%; the management has utilized Rs3bn of the macro prudential buffer in the MFI segment and has a balance of Rs2.25bn as provision buffer. RoA and RoE for the quarter improved marginally to 2.37% and 10.86%, respectively.

## Expects H2 to show improvements across growth, credit costs, and margins

With MFI stress expected to peak in Q2 and normalize by Q3, and festive demand likely to be strong, the management reiterated its FY26 growth guidance of ~22–25%. Credit costs are expected to ease as benefits from Cyclops implementation start to materialize, increasing the share of prime customers with pressure from the MFI segment subsiding. However, the yield will also see some moderation, owing to the changing product mix and cyclops implementation, leading to better quality customer selection, with NIM + fee staying at ~10-10.5%. The mgmt also plans to create a macro buffer (not product-specific) from the recovery in SR book's resolution (FY27-28). With these strategies and tech in place, execution remains the key to improved profitability. Overall, the mgmt sees exit quarter RoA in FY26 at ~2.5% and at ~2.8% in FY27.

Target Price – 12M	Jun-26
Change in TP (%)	5.6
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(6.4)

Stock Data	LTF IN
52-week High (Rs)	213
52-week Low (Rs)	129
Shares outstanding (mn)	2,497.7
Market-cap (Rs bn)	507
Market-cap (USD mn)	5,889
Net-debt, FY26E (Rs mn)	NA
ADTV-3M (mn shares)	6
ADTV-3M (Rs mn)	1,446.3
ADTV-3M (USD mn)	16.8
Free float (%)	32.2
Nifty-50	24,968.4
INR/USD	86.2


## Shareholding, Jun-25

Promoters (%)	66.2
FPIs/MFs (%)	6.2/14.1

## Price Performance

(%)	1M	3M	12M
Absolute	7.6	24.1	10.1
Rel. to Nifty	6.9	18.6	9.3

## 1-Year share price trend (Rs)



## L&amp;T Finance: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Net profits	23,171	26,434	29,941	39,323	50,249
AUM growth (%)	5.8	14.3	18.4	20.7	21.5
NII growth (%)	11.4	15.0	15.5	21.8	21.1
NIMs (%)	10.4	10.8	10.7	10.8	10.7
PPOP growth (%)	(30.2)	15.3	12.2	24.9	24.5
Adj. EPS (Rs)	9.3	10.7	12.1	15.9	20.2
Adj. EPS growth (%)	42.0	15.0	13.1	31.1	27.6
Adj. BV (INR)	92.6	100.9	109.0	119.8	134.9
Adj. BVPS growth (%)	8.7	8.8	8.1	10.0	12.7
RoA (%)	2.2	2.4	2.3	2.6	2.8
RoE (%)	10.3	10.9	11.3	13.6	15.6
P/E (x)	21.8	19.0	17.2	13.3	10.3
P/ABV (x)	2.2	2.0	1.9	1.7	1.5

Source: Company, Emkay Research

## Avinash Singh

 avinash.singh@emkayglobal.com  
 +91-22-662121327

## Kishan Rungta

 kishan.rungta@emkayglobal.com  
 +91-22-66242490

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

**Factoring in Q1 development; maintain REDUCE; raise TP by 6% to Rs190**

To reflect the Q1 performance/developments in the MFI and Gold segments, we slightly increased our disbursement and AUM growth for FY26-28E, with a marginal improvement of ~3-10bps in margins; this resulted in a 3-5% increase in EPS over FY26-28E. We retain REDUCE with an increased Jun-26E TP to Rs190 (up by ~6%), implying FY27E P/B of 1.6x (as valuation is near fair zone after the recent outperformance of the shares and profitability is going to stay stable, with some uncertainty over the near term emerging from factors such as Bihar assembly elections and seasoning of the new unsecured loan book).

**Exhibit 1: Actual vs Estimates**

LTFH Q1FY26					Actual	Change		Emkay Estimates			
Result Update	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	QoQ	YoY	1QFY26	Variation	Consensus	Variation
NII	21,012	21,781	22,371	21,501	22,788	6.0%	8.4%	22,407	1.7%		
Net Income	24,332	25,477	25,359	24,274	26,239	8.1%	7.8%	25,405	3.3%		
Opex	9,656	9,578	10,578	10,034	10,486	4.5%	8.6%	10,433	0.5%		
PPOP	14,676	15,899	14,781	14,240	15,753	10.6%	7.3%	14,973	5.2%	15,458	1.9%
Provision	5,453	6,504	6,542	6,185	6,320	2.2%	15.9%	5,817	8.6%	6,379	-0.9%
PBT	9,223	9,396	8,239	8,055	9,432	17.1%	2.3%	9,156	3.0%	9,079	3.9%
PAT	6,853	6,967	6,257	6,358	7,008	10.2%	2.3%	6,803	3.0%	6,809	2.9%
AUM	887,170	930,140	951,200	977,620	1,023,140	4.7%	15.3%	1,021,127	0.2%		
Disbursement	150,190	151,640	152,100	149,140	175,220	17.5%	16.7%	175,200	0.0%		
Retail AUM	844,450	889,760	922,240	951,800	998,160	4.9%	18.2%	998,000	0.0%		
Retail Disbursement	148,390	150,920	152,100	148,990	175,220	17.6%	18.1%	175,100	0.1%		
Credit Cost (calc.)	2.50%	2.86%	2.78%	2.57%	2.53%	-4bps	2bps	2.3%	20bps		
GS3	3.14%	3.19%	3.23%	3.29%	3.31%	2bps	17bps	3.24%	7bps		
NS3	0.79%	0.96%	0.97%	0.97%	0.99%	2bps	20bps	0.96%	3bps		
PCR	75.33%	70.58%	70.57%	71.13%	70.83%	-31bps	-451bps	71.0%	-17bps		

Source: Company, Emkay Research

**Exhibit 2: Change in estimates**

Y/E Mar (Rs m)	FY26E			FY27E			FY28E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
AUM	1,149,446	1,157,814	0.7%	1,385,485	1,397,117	0.8%	1,683,614	1,698,070	0.9%
Disbursement	696,401	724,770	4.1%	829,654	864,278	4.2%	995,945	1,039,993	4.4%
Disbursement growth (%)	15.5	20.2	470bps	19	19.2	11bps	20	20.3	29bps
AUM Growth (%)	17.6	18.4	86bps	21	20.7	13bps	22	21.5	2bps
Net worth	275,504	276,459	0.3%	301,660	304,412	0.9%	338,709	343,363	1.4%
Net interest income	98,797	100,136	1.4%	120,052	121,964	1.6%	146,041	147,671	1.1%
Total Income	111,791	114,078	2.0%	134,550	137,854	2.5%	162,471	165,762	2.0%
Operating Exp	46,861	47,024	0.3%	53,518	53,890	0.7%	60,832	61,248	0.7%
PPOP	64,930	67,054	3.3%	81,032	83,965	3.6%	101,639	104,513	2.8%
Provision	25,707	26,546	3.3%	30,076	30,590	1.7%	36,022	36,338	0.9%
PAT	29,142	30,097	3.3%	37,860	39,657	4.7%	48,753	50,655	3.9%
EPS (Rs)	11.8	12.2	3.2%	15	16.0	4.7%	20	20.4	3.9%
BV (Rs)	110.4	110.8	0.3%	121	122.0	0.9%	136	137.6	1.4%
NIM (%)	9.29	9.38	9bps	9.47	9.55	8bps	9.52	9.54	3bps
NIMs + Fess (%)	10.51	10.68	17bps	10.62	10.79	18bps	10.59	10.71	12bps
Cost-to-income ratio (%)	41.92	41.22	-70bps	39.78	39.09	-68bps	37.44	36.95	-49bps
Opex-to-AUM	4.41	4.40	0bps	4.22	4.22	0bps	3.96	3.96	-1bps
Credit Costs (%)	2.42	2.49	7bps	2.37	2.39	2bps	2.35	2.35	0bps
RoA (%)	2.31	2.35	4bps	2.61	2.66	5bps	2.82	2.86	4bps
RoE (%)	11.07	11.40	34bps	13.20	13.74	53bps	15.30	15.72	41bps

Source: Company, Emkay Research

## Exhibit 3: Valuation matrix

				P/ABV (x)			P/E (x)			RoA (%)			RoE (%)			Book Value (Rs/sh)			EPS (Rs)		
	CMP/TP (Rs)	Upside	Mkt Cap (Rs bn)	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
At current market price	210.6	-9.8%	526.0	1.9	1.7	1.5	17.3	13.2	10.3	2.3	2.7	2.9	11.4	13.7	15.7	111	122	138	12	16	20
At target price	190.0			1.7	1.6	1.4	15.6	11.9	9.3	2.3	2.7	2.9	11.4	13.7	15.7	111	122	138	12	16	20

Source: Company, Emkay Research

## Exhibit 4: Quarterly earnings snapshot

Particulars (Rs mn)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	YoY	QoQ
Income from operations	34,526	36,544	38,064	37,499	39,145	13.4%	4.4%
Interest Expenses	13,514	14,763	15,692	15,998	16,357	21.0%	2.2%
<b>Net Interest Income</b>	<b>21,012</b>	<b>21,781</b>	<b>22,371</b>	<b>21,501</b>	<b>22,788</b>	<b>8.4%</b>	<b>6.0%</b>
Other Income	3,320	3,696	2,988	2,773	3,451	3.9%	24.4%
<b>Total Income</b>	<b>24,332</b>	<b>25,477</b>	<b>25,359</b>	<b>24,274</b>	<b>26,239</b>	<b>7.8%</b>	<b>8.1%</b>
Operating Expenses	9,656	9,578	10,578	10,034	10,486	8.6%	4.5%
<b>PPoP</b>	<b>14,676</b>	<b>15,899</b>	<b>14,781</b>	<b>14,240</b>	<b>15,753</b>	<b>7.3%</b>	<b>10.6%</b>
Provisions	5,453	6,504	6,542	6,185	6,320	15.9%	2.2%
Credit costs	2.5%	2.9%	2.8%	2.6%	2.5%	2bps	-4bps
<b>PBT</b>	<b>9,223</b>	<b>9,396</b>	<b>8,239</b>	<b>8,055</b>	<b>9,432</b>	<b>2.3%</b>	<b>17.1%</b>
Tax	2,370	2,429	1,983	1,697	2,424	2.3%	42.8%
Tax rate	25.7%	25.9%	24.1%	21.1%	25.7%		
<b>Profit after tax</b>	<b>6,853</b>	<b>6,967</b>	<b>6,257</b>	<b>6,358</b>	<b>7,008</b>	<b>2.3%</b>	<b>10.2%</b>
Share of profit from associates/MI	0	0	0	0	0		
<b>PAT adjusting for one-offs</b>	<b>6,853</b>	<b>6,967</b>	<b>6,257</b>	<b>6,358</b>	<b>7,008</b>	<b>2.3%</b>	<b>10.2%</b>
AUM	887,170	930,140	951,200	977,620	1,023,140	15.3%	4.7%
Disbursement	150,190	151,640	152,100	149,140	175,220	16.7%	17.5%
Net worth	235,290	242,678	249,102	255,641	255,855	8.7%	0.1%
Credit cost	2.50%	2.86%	2.78%	2.57%	2.53%	2bps	-4bps
GS3	3.14%	3.19%	3.23%	3.29%	3.31%	17bps	2bps
NS3	0.79%	0.96%	0.97%	0.97%	0.99%	20bps	2bps
PCR	75.3%	70.6%	70.6%	71.1%	70.8%	-451bps	-31bps

Source: Company, Emkay Research

## Exhibit 5: AUM trend and mix

AUM mix (Rs bn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Overall AUM	787	818	856	887	930	951	978	1,023
Growth	0%	4%	5%	4%	5%	2%	3%	5%
Retail	694	748	800	844	890	922	952	998
Retail growth	8%	8%	7%	6%	5%	4%	3%	5%
Retail AUM as % of overall AUM	88	91	94	95	96	97	97	98
Wholesale	93	70	55	43	40	29	26	25
Wholesale growth	-34%	-24%	-21%	-23%	-5%	-28%	-11%	-3%
Wholesale AUM as % of overall AUM	12	9	6	5	4	3	3	2

Source: Company, Emkay Research

## Exhibit 6: Disbursement trend


Disbursement (Rs bn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
Retail Disbursement	135	145	150	148	151	152	149	175
Growth	20.6%	7.6%	3.5%	-1.4%	1.7%	0.8%	-2.0%	17.6%
Overall Disbursement	137	149	154	150	152	152	149	175
Growth	10.8%	8.5%	3.4%	-2.3%	1.0%	0.3%	-1.9%	17.5%

Source: Company, Emkay Research

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a


## Results in charts

**Exhibit 7: Growth supported by addition of gold segment**




Source: Company, Emkay Research

**Exhibit 8: Retailization at 98%**




Source: Company, Emkay Research

**Exhibit 9: Strong disbursement across retail product segments**




Source: Company, Emkay Research

**Exhibit 10: CoF moderation led by RBI's rate-cut benefit**




Source: Company, Emkay Research

**Exhibit 11: Margin improvement led by an increasing share of high-yield products**




Source: Company, Emkay Research


**Exhibit 12: Stable operating expenses**




Source: Company, Emkay Research

**Exhibit 13: LTF has utilized Rs3bn from macro overlay**


Source: Company, Emkay Research

**Exhibit 14: Asset quality was impacted a tad on continued pressure in MFI segment**

Source: Company, Emkay Research

**Exhibit 15: Marginal improvement in profitability led by improving margins**


Source: Company, Emkay Research

**Exhibit 16: Retail AUM mix – GL added to the portfolio**

Source: Company, Emkay Research


## Story in charts

**Exhibit 17: AUM growth led by strong disbursement**




Source: Company, Emkay Research

**Exhibit 18: Strong disbursement across retail product segments**




Source: Company, Emkay Research

**Exhibit 19: Risk-adjusted yields to remain broadly stable**




Source: Company, Emkay Research

**Exhibit 20: Margin improvement led by increasing share of high yield**




Source: Company, Emkay Research

**Exhibit 21: Opex to see a marginal elevation on account of geographical diversification**




Source: Company, Emkay Research


**Exhibit 22: As share of prime and near prime customers increase; credit cost to improve ahead**



Source: Company, Emkay Research

**Exhibit 23: Asset quality to remain stable**

Source: Company, Emkay Research

**Exhibit 24: Profitability improvement led by improving margins and moderating credit cost**

Source: Company, Emkay Research

## Earnings Call Highlights

- L&T Finance posted its highest-ever consolidated book of Rs1.02trn, with the retail book at Rs998.2mn, up 18% YoY. Retail disbursements for the quarter came at Rs175.22bn, up 18% YoY. Farm equipment finance saw a 16% YoY growth; personal loans surged 65% YoY; housing loans grew 24% YoY, and SME disbursements rose 30% YoY. Rural Business Finance disbursement grew 10% QoQ, driven by better collections, though Karnataka's collection efficiency remains under recovery.
- Gold loan business acquired from Paul Merchants added **Rs13.35bn** to the book, and LTF disbursed ~Rs1.95bn in Q1. The mgmt also informed that integration was completed in under two months, with 130 branches and 700 employees onboarded; it plans to add 170 branches (taking the count to over 300) in FY26.
- Technology Update: Project Cyclops is fully deployed across 2W dealerships and for ~20% of tractor dealerships. This has started showing good results. This implementation has resulted in net non-starters in 2Ws dropping to 0.34% (Jun-25), from 2.36% (Dec-24). Full rollout of project Cyclops in tractors and SMEs is expected to be completed by Q2FY26, and in personal loans by Q3FY26.
- Project Nostradamus, the real-time AI portfolio monitoring engine, is on track for a beta launch in Sep-25 and early warning dashboards are already live.
- Lakshya 2026 goals:
  - Retaliation – Target of 95% vs 98% achieved.
  - Growth – Retail growth of 25%. The company plans to grow in a risk-calibrated manner and saw a CAGR of 28% over FY22-25.
  - Asset Quality – GS3/NS3 at 3.31%/0.99%, with improvement expected as stress in MFI eases (GS3 target of <3%).
  - RoA – Targets RoA of 2.8-3.0%. RoA has improved by 15bps QoQ and is expected to further improve to 2.5% in FY26.
- Normalized credit cost is expected to remain contained at 2.3-2.5% (including utilization of the macro prudential buffer) in FY26. The mgmt expects it to moderate further, led by adoption of project Cyclops across product segments.
- Two-wheeler disbursement quality improved, led by implementation of project Cyclops, and an increasing share of prime customers (84%; up from 53% in Mar-24). The mgmt expected disbursements to pick up in this segment and sees asset quality improving further as legacy loans run down.
- The mgmt also informed that the overall yield might moderate ~20-30bps as it continues to build prime and near-prime customer books; on a risk-adjusted basis though, overall profitability is going to improve, led by the benefit coming in from moderating credit cost.
- Despite heatwaves, elections, and a higher borrower leverage, LTF sees steady improvement in collection trends. The Karnataka ordinance had a short-term impact, and recovery is underway. Bihar collections are stable.
- **Guidance:**
  - AUM to grow at 22-25%.
  - Credit cost to contain at 2.3-2.5%.
  - Cost to see a marginal elevation on account of the new GL branch addition and geographical expansion.
  - Disbursements would not be impacted in SME/PL segments, on account of the implementation of Cyclops.
  - LTF will be partnering with a few big tech companies; announcement to follow.
  - RoA to reach ~2.8% by end-FY27, with FY26 target of 2.5%.
  - Resolution of the SR book is in advanced stages and should be done by FY27-28; we expect proceeds to be utilized to build macro provision (not specific to any segment).

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a



L&T Finance: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Interest Income	129,139	146,633	168,667	201,162	242,151
Interest Expense	53,772	59,968	68,531	79,198	94,480
Net interest income	75,367	86,665	100,136	121,964	147,671
NII growth (%)	11.4	15.0	15.5	21.8	21.1
Non interest income	11,412	12,777	13,732	15,440	17,544
Total income	86,779	99,442	113,868	137,404	165,216
Operating expenses	35,079	39,846	47,024	53,890	61,248
PPOP	51,701	59,597	66,844	83,515	103,967
PPOP growth (%)	(30.2)	15.3	12.2	24.9	24.5
Provisions & contingencies	21,410	24,684	26,546	30,590	36,338
PBT	30,290	34,913	40,298	52,924	67,630
Extraordinary items	0	0	0	0	0
Tax expense	7,119	8,478	10,356	13,602	17,381
Minority interest	(30)	245	245	245	245
Income from JV/Associates	0	0	0	0	0
Reported PAT	23,171	26,434	29,941	39,323	50,249
PAT growth (%)	50.8	14.1	13.3	31.3	27.8
Adjusted PAT	23,171	26,434	29,941	39,323	50,249
Diluted EPS (Rs)	9.3	10.7	12.1	15.9	20.2
Diluted EPS growth (%)	42.0	15.0	13.1	31.1	27.6
DPS (Rs)	2.5	2.8	3.8	4.8	4.8
Dividend payout (%)	26.9	25.7	25.0	25.0	25.0
Effective tax rate (%)	23.5	24.3	25.7	25.7	25.7
Net interest margins (%)	10.4	10.8	10.7	10.8	10.7
Cost-income ratio (%)	40.4	40.1	41.3	39.2	37.1
PAT/PPOP (%)	44.8	44.8	45.2	47.4	48.6
Shares outstanding (mn)	2,488.9	2,494.9	2,494.9	2,494.9	2,494.9

Source: Company, Emkay Research

Asset quality and other metrics					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Asset quality					
GNPL - Stage 3	26,980	32,180	37,050	44,009	52,640
NNPL - Stage 3	6,610	9,290	11,115	13,203	15,792
GNPL ratio - Stage 3 (%)	3.2	3.3	3.2	3.2	3.1
NNPL ratio - Stage 3 (%)	0.8	1.0	1.0	1.0	1.0
ECL coverage - Stage 3 (%)	75.5	71.1	70.0	70.0	70.0
ECL coverage - 1 & 2 (%)	2.7	1.8	2.0	2.0	2.0
Gross slippage - Stage 3	-	-	-	-	-
Gross slippage ratio (%)	-	-	-	-	-
Write-off ratio (%)	0.6	0.3	1.2	1.1	1.1
Total credit costs (%)	2.6	2.7	2.5	2.4	2.3
NNPA to networth (%)	2.8	3.6	4.0	4.3	4.6
Capital adequacy					
Total CAR (%)	22.8	21.4	20.2	19.1	18.2
Tier-1 (%)	21.0	19.6	18.4	17.3	16.3
Miscellaneous					
Total income growth (%)	(15.3)	14.6	14.5	20.7	20.2
Opex growth (%)	23.8	13.6	18.0	14.6	13.7
PPOP margin (%)	6.2	6.5	6.3	6.5	6.7
Credit costs-to-PPOP (%)	41.4	41.4	39.7	36.6	35.0
Loan-to-Assets (%)	79.2	77.9	80.3	82.6	84.3
Yield on loans (%)	15.5	16.0	15.8	15.7	15.6
Cost of funds (%)	6.7	7.1	6.9	6.7	6.7
Spread (%)	8.8	8.9	8.9	9.0	9.0

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	24,889	24,949	24,949	24,949	24,949
Reserves & surplus	209,495	230,692	251,355	278,973	317,518
Net worth	234,384	255,641	276,303	303,922	342,467
Borrowings	765,409	922,469	1,076,767	1,285,348	1,553,734
Other liabilities & prov.	27,382	26,655	28,918	31,608	34,752
Total liabilities & equity	1,027,176	1,204,764	1,381,988	1,620,878	1,930,953
Net loans	813,594	937,731	1,109,464	1,339,249	1,628,314
Investments	123,849	118,760	129,212	115,681	77,687
Cash, other balances	46,760	108,329	103,225	123,282	177,527
Interest earning assets	984,203	1,164,820	1,341,901	1,578,212	1,883,527
Fixed assets	5,416	7,166	8,957	11,196	13,995
Other assets	37,557	32,549	31,130	31,470	33,431
Total assets	1,027,176	1,204,534	1,381,988	1,620,878	1,930,953
BVPS (Rs)	94.2	102.5	110.7	121.8	137.3
Adj. BVPS (INR)	92.6	100.9	109.0	119.8	134.9
Gross loans	855,640	977,620	1,157,814	1,397,117	1,698,070
Total AUM	855,640	977,620	1,157,814	1,397,117	1,698,070
On balance sheet	-	-	-	-	-
Off balance sheet	-	-	-	-	-
Disbursements	562,930	603,030	704,770	839,278	1,007,493
Disbursements growth (%)	19.8	7.1	16.9	19.1	20.0
Loan growth (%)	8.3	15.3	18.3	20.7	21.6
AUM growth (%)	5.8	14.3	18.4	20.7	21.5
Borrowings growth (%)	(7.8)	20.5	16.7	19.4	20.9
Book value growth (%)	8.7	8.8	8.1	10.0	12.7

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	21.8	19.0	17.2	13.3	10.3
P/B (x)	2.2	2.0	1.8	1.7	1.5
P/ABV (x)	2.2	2.0	1.9	1.7	1.5
P/PPOP (x)	0.0	0.0	0.0	0.0	0.0
Dividend yield (%)	1.2	1.4	1.9	2.4	2.4
Dupont-RoE split (%)					
NII/avg AUM	9.1	9.5	9.4	9.5	9.5
Other income	1.4	1.4	1.3	1.2	1.1
Securitization income	-	-	-	-	-
Opex	2.0	1.9	1.9	1.8	1.7
Employee expense	2.2	2.4	2.5	2.4	2.3
PPOP	6.2	6.5	6.3	6.5	6.7
Provisions	2.6	2.7	2.5	2.4	2.3
Tax expense	0.9	0.9	1.0	1.1	1.1
RoAUM (%)	2.8	2.9	2.8	3.1	3.3
Leverage ratio (x)	3.7	3.7	4.0	4.4	4.8
RoE (%)	10.3	10.9	11.3	13.6	15.6

Quarterly data					
Rs mn, Y/E Mar	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26
NII	21,012	21,781	22,371	21,501	22,788
NIM (%)	11.2	11.2	10.8	10.1	10.5
PPOP	14,676	15,899	14,781	14,240	15,753
PAT	6,853	6,967	6,257	6,358	7,008
EPS (Rs)	2.75	2.79	2.51	2.55	2.81


Source: Company, Emkay Research

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
07-Jul-25	208	180	Reduce	Avinash Singh
20-Jun-25	190	150	Reduce	Avinash Singh
05-Jun-25	183	150	Reduce	Avinash Singh
29-Apr-25	168	150	Reduce	Avinash Singh
10-Apr-25	153	140	Reduce	Avinash Singh
03-Apr-25	154	140	Reduce	Avinash Singh
27-Feb-25	139	140	Reduce	Avinash Singh
21-Jan-25	146	140	Reduce	Avinash Singh
06-Jan-25	138	150	Reduce	Avinash Singh
30-Dec-24	136	150	Reduce	Avinash Singh
05-Dec-24	148	150	Reduce	Avinash Singh
26-Nov-24	141	150	Reduce	Avinash Singh
21-Oct-24	158	150	Reduce	Avinash Singh
04-Oct-24	175	210	Add	Avinash Singh
02-Sep-24	171	210	Add	Avinash Singh
20-Aug-24	167	210	Add	Avinash Singh
18-Jul-24	185	210	Add	Avinash Singh
04-Jul-24	188	200	Add	Avinash Singh
05-Jun-24	157	190	Add	Avinash Singh
30-Apr-24	167	190	Add	Avinash Singh

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 21, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

**Disclosure of previous investment recommendation produced:**

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 21, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 21, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	>15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: [www.emkayglobal.com](http://www.emkayglobal.com)This report is intended for Team White Marquee Solutions ([team.emkay@whitemarquesolutions.com](mailto:team.emkay@whitemarquesolutions.com)) use and downloaded a

**OTHER DISCLAIMERS AND DISCLOSURES:**

**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.